Search research articles
Contact Us
Filters
Showing results (51-60 of 63) with videos related to
Page
of 7
Sort By:
Molecular Cancer Therapeutics
|
December 19, 2006
Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors
Emma Kulimova, Elisabeth Oelmann, Guido Bisping, et al.
Haematologica
|
July 30, 2016
Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center
Michele Pohlen, Julia Marx, Alexander Mellmann, et al.
Oncotarget
|
October 15, 2016
Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction
Janine Stucke-Ring, Julian Ronnacker, Caroline Brand, et al.
Cancer Immunology Research
|
February 13, 2015
Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation
Christoph Schliemann, Katrin L Gutbrodt, Andrea Kerkhoff, et al.
Translational Oncology
|
August 21, 2018
Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma
Torsten Kessler, Ariane Baumeier, Caroline Brand, et al.
Blood Neoplasia
|
January 9, 2026
Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022
Andrew F Berdel, Julian Ronnacker, Daniela V Wenge, et al.
Blood
|
November 10, 2005
Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups
Guido Bisping, Martin Kropff, Doris Wenning, et al.
Acta Haematologica
|
April 12, 2017
Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis
Gabriela B Thoennissen, Dennis Görlich, Ulrike Bacher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2003
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group
Thomas Büchner, Wolfgang Hiddemann, Wolfgang E Berdel, et al.
Critical Reviews in Oncology/Hematology
|
October 26, 2005
Treatment of older patients with AML
Thomas Büchner, Wolfgang E Berdel, Bernhard Wörmann, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 63) with videos related to
Sort By:
Page
of 7
Molecular Cancer Therapeutics
|
December 19, 2006
Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors
Emma Kulimova, Elisabeth Oelmann, Guido Bisping, et al.
Haematologica
|
July 30, 2016
Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center
Michele Pohlen, Julia Marx, Alexander Mellmann, et al.
Oncotarget
|
October 15, 2016
Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction
Janine Stucke-Ring, Julian Ronnacker, Caroline Brand, et al.
Cancer Immunology Research
|
February 13, 2015
Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation
Christoph Schliemann, Katrin L Gutbrodt, Andrea Kerkhoff, et al.
Translational Oncology
|
August 21, 2018
Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma
Torsten Kessler, Ariane Baumeier, Caroline Brand, et al.
Blood Neoplasia
|
January 9, 2026
Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022
Andrew F Berdel, Julian Ronnacker, Daniela V Wenge, et al.
Blood
|
November 10, 2005
Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups
Guido Bisping, Martin Kropff, Doris Wenning, et al.
Acta Haematologica
|
April 12, 2017
Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis
Gabriela B Thoennissen, Dennis Görlich, Ulrike Bacher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2003
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group
Thomas Büchner, Wolfgang Hiddemann, Wolfgang E Berdel, et al.
Critical Reviews in Oncology/Hematology
|
October 26, 2005
Treatment of older patients with AML
Thomas Büchner, Wolfgang E Berdel, Bernhard Wörmann, et al.
Page
of 7